CClinicalTrials.gg
CompletedNCT04891393Updated Apr 8, 2022

The Effects of Caffeine on Human Spinal Motoneurons

An interventional study of Coffee and Decaffeinated coffee in Healthy, sponsored by Temple University. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-08.

Sponsored by Temple University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study evaluates the effects of orally ingested, commercially available, coffee (3 mg/kg of caffeine) on the excitability of human spinal motoneurons of the lower leg.

Read the detailed description

Recently, it has been shown that human spinal motoneurons do not simply act as a binary control system. Instead, they are regulated by intrinsic properties that can elicit lingering effects on the descending motoneuron. Caffeine, one of the world's most popular over-the-counter supplements, can potentially augment these characteristics of motoneurons. Using decomposition software and non-invasive, high-density surface electromyography, it is possible to extract the characteristics of these motoneurons. This project will utilize a double-blind, inactive-placebo controlled, crossover design study to examine and quantify the effects of caffeine on motoneuron excitability.

02

Conditions studied

  • Healthy

Keywords

  • Motor Neuron
  • Excitability
  • Caffeine
03

In context

Lead sponsor

Temple University is the lead sponsor of 219 studies on the registry; 30 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 7 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

● Between 18 and 70 years of age

Exclusion criteria

Exclusion Criteria:

  • Significant neurological or orthopedic injuries, which may limit volitional torque generation in the tested muscles.
  • Significant change in the subjects' health or treatment in the past month.
  • Known history of cardiovascular pathology (to include: uncontrolled hypertension, cardiac arrhythmias) or medical restrictions to caffeine ingestion.
  • Allergies or dislike of coffee.
  • Women who are pregnant will be excluded due to potential forces at trunk from pelvic safety harness and due to potential adverse effects of caffeine on the developing child.
  • Women who are breastfeeding will be excluded due potential adverse effects on the breastfeeding infant from caffeine administration.
  • Adults unable to consent, minors, pregnant women, and prisoners will not be included.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Caffeine

    Single-dose, orally ingested, instant coffee.

    Dietary Supplement: Coffee

  • Placebo comparator
    Inactive Placebo

    Single-dose, orally ingested, instant decaffeinated coffee (equal weight to intervention dose).

    Dietary Supplement: Decaffeinated coffee

Interventions

  • Dietary supplementCoffee

    Starbucks brand "Via" instant coffee. (Caffeine Content: 3 mg / kg)

  • Dietary supplementDecaffeinated coffee

    Starbucks brand "Via" instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)

06

What researchers measure

Primary outcomes

  1. Motoneuron excitability (Delta-f)

    Changes in motorneuron excitability, as quantified by Delta-F values. A paired motor unit technique will be utilized (Gorassini et al., 2002). (Typically, these values range from -5 to +10).

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

Secondary outcomes

  1. Motor Unit Discharge Rate

    Changes in motor unit discharge rate. This is a single value that ranges from, approximately, 0 to 30.

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

  2. Coherence

    Changes in coherence values. Coherence provides a normalized value of the strength of correlation in the frequency domain. The magnitude of the correlation of the Fourier transforms of two spike trains is squared producing a value between 0 and 1, with 1 corresponding to a perfect linear prediction at a particular frequency (Rosenberg et al., 1989). This will be calculated using the composite spike train (Negro \& Farina, 2012) and, finally, z-transformed to allow for between-trial comparisons.

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

  3. Motor Unit Recruitment Threshold

    Changes in motor unit recruitment threshold. As assessed by determining the amount of force (percentage of maximum volitional force output) needed to recruit an individual motor unit.

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

07

Study locations

1 site
  • Temple University
    Philadelphia, Pennsylvania 19122, United States
08

References and documents

Publications

  • Gorassini M, Yang JF, Siu M, Bennett DJ. Intrinsic activation of human motoneurons: possible contribution to motor unit excitation. J Neurophysiol. 2002 Apr;87(4):1850-8. doi: 10.1152/jn.00024.2001. PubMed 11929906 ↗
  • Rosenberg JR, Amjad AM, Breeze P, Brillinger DR, Halliday DM. The Fourier approach to the identification of functional coupling between neuronal spike trains. Prog Biophys Mol Biol. 1989;53(1):1-31. doi: 10.1016/0079-6107(89)90004-7. No abstract available. PubMed 2682781 ↗
  • Farina D, Negro F. Accessing the neural drive to muscle and translation to neurorehabilitation technologies. IEEE Rev Biomed Eng. 2012;5:3-14. doi: 10.1109/RBME.2012.2183586. PubMed 23231985 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04891393
Lead sponsor
Temple University
Responsible party
Sponsor
First posted
May 18, 2021
Start date
Jun 1, 2021
Primary completion
Mar 28, 2022
Completion
Mar 28, 2022
Last update
Apr 8, 2022

Study contacts

Christopher Thompson, PT, PhD
principal investigator · Temple University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion